<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-141 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-141</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-141</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-6.html">extraction-schema-6</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <p><strong>Paper ID:</strong> paper-99c46d7cc3bbc778e54117c4468985219f33e137</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/99c46d7cc3bbc778e54117c4468985219f33e137" target="_blank">Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function</a></p>
                <p><strong>Paper Venue:</strong> Nature Genetics</p>
                <p><strong>Paper TL;DR:</strong> This meta-analysis included 20,890 participants of European ancestry from four CHARGE Consortium studies: Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study and Rotterdam Study, and identified eight loci associated with FEV1/FVC and one locus at or near genome-wide significance in theCHARGE Consortium dataset.</p>
                <p><strong>Cost:</strong> 0.025</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e141.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e141.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CHARGE GWAS meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) meta-analysis of genome-wide association studies for pulmonary function</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Meta-analysis of GWAS results for FEV1 and FEV1/FVC in 20,890 European-ancestry adults from four population cohorts, identifying multiple loci associated with pulmonary function and exploring smoking-stratified effects.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>meta-analysis of genome-wide association studies</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>20,890 adults of European ancestry from four cohorts (ARIC N=7,980; CHS N=3,140; FHS N=7,694; Rotterdam Study RS-I+RS-II N=2,076). Ever smokers N=11,963; never smokers N=8,927. Both sexes; adult participants across a range of ages represented in cohort studies.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Genetic loci associated with lower pulmonary function (FEV1 or FEV1/FVC) that may increase susceptibility to smoking-related lung disease: HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A, PTCH1, PID1, HTR4 (FEV1/FVC) and INTS12-GSTCD-NPNT (FEV1). Smoking status and cumulative exposure (pack-years) were strong behavioral risk factors for accelerated decline in pulmonary function.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Never-smoking and lower cumulative smoking (pack-years) are protective; smoking cessation is implied protective (genetic variant in FLJ20184 previously associated with cessation was noted). No specific genetic 'protective' alleles for lung cancer are proven here, though variants potentially involving efficient detoxification (GSTCD) or better repair/inflammation control are hypothesized to be protective.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Heritability of pulmonary function cited >40% in prior literature. This study identified genome-wide significant loci: for FEV1/FVC — HHIP (top SNP rs1980057, P=4.90×10^-11), GPR126 (rs3817928, P=2.60×10^-10), ADAM19, AGER-PPT2 (including rs2070600, non-synonymous), FAM13A, PTCH1, PID1, HTR4; for FEV1 — a locus on 4q24 spanning INTS12-GSTCD-NPNT (top SNP rs17331332, P=4.00×10^-10). Some loci replicated in the independent SpiroMeta consortium; others (FAM13A, PTCH1, PID1) did not replicate. Effect sizes: per-allele FEV1 change ~56–71 mL; per-allele FEV1/FVC change ~0.44–1.14%. The study notes α1-antitrypsin deficiency is an established (rare) genetic risk factor for COPD, especially in smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Current/past/never smoking status and pack-years (quantity × duration) were adjusted and examined; nicotine dependence loci (CHRNA3/5) are discussed as modifiers of exposure because they influence smoking intensity; FLJ20184 noted from other work to be associated with smoking cessation, which modifies risk.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Primary environmental modifier discussed is tobacco smoke (active smoking and second-hand smoke). Other inhaled pollutants and hyperoxia are mentioned as contributors/modifiers. Quantitative second-hand smoke impacts on FEV1 cited: 10-year home exposure = –15 mL; 10-year workplace exposure = –41 mL (reference study).</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Mechanistic themes linked to the loci include: hedgehog (Hh) signaling (HHIP, PTCH1) involved in lung development and epithelial injury response; AGER (RAGE) involvement in inflammation and tissue remodeling; HTR4 (serotonin receptor) in airway reactivity and cytokine release; ADAM family (ADAM19/ADAM33) in cell-matrix interactions and tissue remodeling; GSTCD in xenobiotic detoxification via glutathione pathways; GPR126 (adhesion GPCR) in developmental signaling; INTS12 (Integrator complex) in RNA processing. These processes (inflammation, detoxification, epithelial repair, and response to injury) are relevant to differential susceptibility to smoking-related lung damage and potentially carcinogenesis.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>CHARGE meta-analysis (N=20,890) genomic control λ_gc = 1.04 (FEV1/FVC). Key SNP results: rs1980057 (near HHIP) P=4.90×10^-11; rs3817928 (GPR126) P=2.60×10^-10; rs17331332 (near NPNT) P=4.00×10^-10; rs2070600 (AGER, non-synonymous) genome-wide significant and replicated in SpiroMeta. Per-allele FEV1 change 55.92–71.43 mL; per-allele FEV1/FVC change 0.44–1.14%. CHRNA3/5 locus SNP rs1051730 had nominal association with FEV1/FVC P=0.00070 in CHARGE but was not significant genome-wide here. Joint CHARGE+SpiroMeta P values for replicated hits ranged down to ~3.21×10^-20 for top SNPs (see paper tables).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Many smokers do not develop clinically significant pulmonary function decline or COPD; α1-antitrypsin deficiency is rare and explains little of population variability. Several loci identified in CHARGE (FAM13A, PTCH1, PID1) did not replicate in SpiroMeta, indicating heterogeneity or false-positive risk signals. Some loci showed stronger signals in never smokers (e.g., many GPR126 SNPs), indicating complex gene-environment interplay.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Cross-sectional GWAS meta-analysis design limits causal inference; cohorts restricted to European ancestry (generalizability limited); limited power to detect small-effect or low-frequency variants; potential residual population stratification despite genomic control; pulmonary function outcomes (FEV1, FEV1/FVC) used as surrogates relevant to COPD and lung health but the study did not directly measure lung cancer incidence or compare smokers who do vs do not develop lung cancer.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e141.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Alpha1-AT</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Alpha-1 antitrypsin deficiency</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A relatively uncommon genetic deficiency known to increase risk of accelerated pulmonary function decline and COPD, particularly among smokers; mentioned as the only established genetic risk factor prior to GWAS findings.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>background mention (clinical genetic risk factor)</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Discussed in background; not specifically analyzed in CHARGE. Prevalence noted as relatively uncommon.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Alpha-1 antitrypsin deficiency increases risk of accelerated pulmonary function decline and COPD among smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Normal alpha-1 antitrypsin function is implied protective relative to deficiency.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Alpha-1 antitrypsin deficiency is the only established genetic risk factor for accelerated pulmonary decline and COPD noted in background; authors state it accounts for little of population variability.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking markedly increases risk in alpha-1 antitrypsin deficient individuals.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Smoking is the primary environmental modifier exacerbating disease in deficiency.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Protease-antiprotease imbalance leading to unchecked proteolytic damage to lung parenchyma (classical mechanism, here only mentioned).</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Although influential in affected individuals, alpha-1 antitrypsin deficiency explains little of population-level variability in pulmonary function.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Mentioned as background; no new data on prevalence/effect sizes in CHARGE.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e141.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HHIP / Hedgehog pathway</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hedgehog interacting protein (HHIP) and hedgehog signaling pathway (including PTCH1)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>HHIP region SNPs were strongly associated with FEV1/FVC; hedgehog signaling is crucial for lung branching morphogenesis and may influence adult airway response to injury (e.g., smoking), implicating developmental and repair pathways in susceptibility to smoking-related lung disease.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Associated in CHARGE analysis of 20,890 European-ancestry participants; several SNPs in HHIP replicated in SpiroMeta.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Common variants near HHIP associated with lower FEV1/FVC (indicator of airflow obstruction) and thus may increase vulnerability to smoking-related airway disease.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>No specific protective alleles defined; intact Hh signaling is implied necessary for normal lung development and repair.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Top CHARGE SNP rs1980057 near HHIP: P=4.90×10^-11; multiple correlated SNPs in region. PTCH1 SNPs were significant in CHARGE but did not replicate in SpiroMeta.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Authors discuss possible interaction with smoking-related injury; hedgehog pathway may mediate airway response to cigarette smoke and hyperoxia.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Cigarette smoke and hyperoxia cited as environmental insults that interact with Hh pathway activity.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Hh signaling (epithelial production of Hh ligand that binds PTCH1 on mesenchymal cells) orchestrates lung patterning and likely contributes to adult airway repair; dysregulation may affect susceptibility to structural airway changes after smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>HHIP top SNP rs1980057 CHARGE P=4.90×10^-11; joint CHARGE+SpiroMeta significance reached P as small as ~3.21×10^-20 for HHIP region variants (per paper summary).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>PTCH1 associations were not confirmed in SpiroMeta, indicating locus-specific heterogeneity.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Functional causal variants not established; mechanistic links to lung cancer are inferred from lung development and injury response literature rather than demonstrated directly in this study.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e141.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AGER (RAGE) rs2070600</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Advanced glycation end-product receptor (AGER), SNP rs2070600 (Gly->Ser)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A non-synonymous variant in AGER associated with FEV1/FVC at genome-wide significance and replicated; AGER is highly expressed in lung and mediates inflammation and tissue remodeling, mechanisms relevant to smoking-related lung damage.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Identified in CHARGE (20,890 European-ancestry participants) and independently confirmed in SpiroMeta.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>The rs2070600 variant is associated with lower FEV1/FVC and is predicted (PolyPhen) to possibly damage protein structure; functionally this variant has been linked to higher ligand affinity and amplified inflammatory responses in prior work.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>No protective allele described; presence of wild-type AGER may be relatively protective compared to function-altering variants.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>rs2070600 (Gly->Ser) reached genome-wide significance for association with FEV1/FVC in CHARGE and was independently confirmed in SpiroMeta. PolyPhen predicts possibly damaging effect.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking likely interacts with AGER-mediated inflammatory signaling, though direct interaction tests with smoking were not the focus here.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Lung exposures that trigger inflammation (including cigarette smoke) are relevant modifiers of AGER signaling.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>AGER (RAGE) is a pattern recognition receptor mediating proinflammatory signaling and tissue remodeling; variant rs2070600 may alter ligand affinity and increase inflammatory responses, plausibly increasing susceptibility to smoking-induced lung injury.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>rs2070600 among genome-wide significant SNPs for FEV1/FVC in CHARGE and replicated in SpiroMeta; exact P-values reported in Supplementary Table 2 and Table 2 (replication) of paper.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>AGER absence has been implicated in pulmonary fibrosis in animal models, indicating complex roles in lung disease beyond simple risk/protection dichotomy.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Functional consequence in human lung disease beyond associations needs further mechanistic/functional validation; link to lung cancer is indirect (inflammation/tissue remodeling pathways).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e141.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CHRNA3/5 locus</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cholinergic nicotinic receptor subunits alpha-3/alpha-5 (CHRNA3/5)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Locus previously implicated in nicotine dependence and COPD; influences smoking behavior (exposure) and was nominally associated with pulmonary function in CHARGE, illustrating gene-environment interplay where genetic predisposition to heavier smoking increases disease risk.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>locus previously reported in COPD GWAS; re-examined in CHARGE</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>CHARGE examined CHRNA3/5 SNPs in their sample (20,890 Europeans); rs1051730 had P=0.00070 for FEV1/FVC in CHARGE.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Variants in CHRNA3/5 increase propensity for heavy smoking (nicotine dependence), indirectly raising exposure-related risk for smoking-related lung disease and thus potentially lung cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Absence of risk alleles would be relatively protective by reducing propensity to heavy smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>CHRNA3/5 has been implicated in prior COPD GWAS and nicotine dependence studies (references in paper). In CHARGE, rs1051730 associated with FEV1/FVC at P=0.00070 (nominal).</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>CHRNA3/5 variants modify smoking intensity and thus cumulative exposure (pack-years), an important behavioral mediator of risk.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not directly addressed beyond tobacco exposure; effect acts by altering smoking behavior/exposure to tobacco smoke.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Acts via nicotine receptor subunits affecting dependence and smoking behavior; behavioral mediation increases carcinogen exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>rs1051730 association with FEV1/FVC in CHARGE P=0.00070; other CHRNA3/5 SNP rs8034191 not associated (P=0.11 for FEV1/FVC).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Nominal association in CHARGE suggests context-dependent effects; CHRNA3/5 may contribute to risk via behavior more than via direct lung tissue susceptibility.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>CHARGE provides only nominal evidence; CHRNA3/5’s role in direct tissue susceptibility vs behavior-mediated risk needs further study.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e141.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>GSTCD / INTS12 / NPNT locus (4q24)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>INTS12-GSTCD-NPNT locus on chromosome 4q24</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Locus spanning INTS12, GSTCD and NPNT showed genome-wide significant associations with FEV1; GSTCD implicates detoxification pathways while NPNT and INTS12 have plausible roles in lung structure/function.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Association observed in CHARGE (N=20,890) and replicated in SpiroMeta (combined sample ~41,000 in joint analyses for replication tests).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Common variants in this locus are associated with lower FEV1 (per-allele effect ~56–71 mL), which could reflect increased susceptibility to smoking-related lung damage and hence increased risk of smoking-related lung disease.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Variants that preserve GSTCD function or other protective alleles not yet identified; intact detoxification by glutathione-S-transferase plausible protective mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Top SNP rs17331332 near NPNT P=4.00×10^-10 in CHARGE; multiple correlated SNPs across the three genes were genome-wide significant; joint meta-analysis with SpiroMeta had P values as small as 4.66×10^-17 to 9.42×10^-14 for replicated SNPs.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Effects were stronger among ever smokers for many SNPs (39 of 46 FEV1-significant SNPs were significant among ever smokers), indicating interaction with smoking exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Exposure to xenobiotics (including cigarette smoke) is the relevant environmental modifier given GSTCD's putative role in detoxification.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>GSTCD (glutathione S-transferase C-terminal domain) could modulate detoxification of inhaled xenobiotics and oxidative stress; NPNT (nephronectin) expressed in fetal and adult lung and may influence lung structure; INTS12 involved in RNA processing—mechanistic links to lung function and response to insults are speculative.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Per-allele FEV1 change in the region ~55.92–71.43 mL. Replicated SNPs in joint meta-analysis P values ranged 4.66×10^-17 to 9.42×10^-14.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Exact causal gene in the region remains unclear due to linkage disequilibrium among multiple adjacent genes.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Functional variants not established; biological mechanisms remain speculative; further fine-mapping required.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e141.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>GPR126</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>G protein-coupled receptor 126 (GPR126)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>GPR126 region SNPs associated with FEV1/FVC at genome-wide significance in CHARGE and in joint analysis; GPR126 belongs to the adhesion GPCR family and is expressed in lung, implicated in development and possibly structural traits (previously associated with height).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Associated in CHARGE (20,890 Europeans); 69 genome-wide significant SNPs in/near GPR126 (top rs3817928 P=2.60×10^-10), with many significant among never smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>GPR126 variants associated with lower FEV1/FVC (indicator of airflow obstruction), potentially increasing susceptibility to smoking-related airflow obstruction.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>No specific protective alleles defined here.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Top SNP rs3817928 P=2.60×10^-10 (CHARGE). Many GPR126 SNPs were genome-wide significant among never smokers, suggesting complex genotype-phenotype relations.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Associations persisted after adjustment for standing and sitting height (to exclude confounding by trunk height), suggesting genetic effect independent of smoking behavior though interaction with smoking was examined.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Not specifically enumerated beyond smoking as a modifier of pulmonary decline.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>GPR126 is an adhesion GPCR; expression is high in adult lung and increased during embryonic organ development, implying roles in lung structure or repair.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>69 genome-wide significant SNPs in GPR126 for FEV1/FVC; top SNP P=2.60×10^-10. Direction of effect largely consistent across cohorts except some cohort inconsistencies noted.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Some GPR126 SNPs showed cohort-specific direction inconsistencies.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Function of GPR126 in adult lung not fully elucidated; replication supports association but mechanisms unknown.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.7">
                <h3 class="extraction-instance">Extracted Data Instance 7 (e141.7)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>ADAM19 / ADAM33 family</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>ADAM19 and the ADAM (a disintegrin and metalloprotease) family (including ADAM33)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>ADAM19 SNPs were genome-wide significant for FEV1/FVC in CHARGE and joint meta-analysis; ADAM family proteins regulate cell-matrix interactions and morphogenesis and have been implicated in bronchial hyperresponsiveness and lung function decline (ADAM33).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis; prior candidate-gene literature</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>ADAM19 associations seen in CHARGE (20,890 Europeans) and joint analysis with SpiroMeta.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Common ADAM19 variants associated with lower FEV1/FVC and thus may predispose to greater smoking-related airflow obstruction.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>No protective variants defined.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>ADAM19 SNPs reached genome-wide significance in CHARGE; prior literature links ADAM33 polymorphisms to bronchial hyperresponsiveness and accelerated lung function decline.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking interacts with airway remodeling processes controlled by ADAM family enzymes, but direct interaction tests not primary focus here.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Exposure/injury from inhaled agents like cigarette smoke are environmental contexts in which ADAM-mediated remodeling is relevant.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>ADAM proteins modulate cell-matrix interactions and may influence airway remodeling, hyperresponsiveness, and repair after injury (processes that mediate progression from smoke exposure to chronic disease).</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>ADAM19 SNPs reached genome-wide significance in CHARGE and joint meta-analysis P values ranged into genome-wide significant range (see Table 2 in paper).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>ADAM19 not previously implicated as strongly as ADAM33; functional work needed to confirm role.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Causal variants and specific functional consequences not yet defined; associations do not by themselves prove mechanism.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.8">
                <h3 class="extraction-instance">Extracted Data Instance 8 (e141.8)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>HTR4</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>5-hydroxytryptamine (serotonin) receptor 4 (HTR4)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>HTR4 locus SNP(s) associated with FEV1/FVC at borderline genome-wide significance in CHARGE and reached genome-wide significance in joint analyses; HTR4 mediates serotonin signaling which affects airway reactivity and pro-inflammatory cytokine release.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>GWAS finding within meta-analysis with biological plausibility discussion</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>HTR4 SNP rs11168048 borderline genome-wide significant in CHARGE (P≈5.37×10^-8) and reached stronger significance in analyses excluding asthma/COPD and in joint meta-analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>HTR4 variants associated with lower FEV1/FVC suggest involvement in airway obstruction susceptibility, potentially increasing risk from smoking-related airway disease.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>No protective alleles specified.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>SNP rs11168048 in HTR4 had borderline genome-wide significance in original meta-analysis and reached genome-wide significance in subset without asthma/COPD and in joint meta-analysis.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Not primarily behavioral; serotonin-mediated effects might interact with inflammatory exposures (including smoke).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Cigarette smoke and other inflammatory exposures may interact with serotonergic signaling in airways.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>HTR4 activation regulates cAMP and modulates cholinergic and immune-mediated airway reactivity; in airway epithelial cells HTR4 regulates release of pro-inflammatory cytokines.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>rs11168048 P ~5.37×10^-8 in CHARGE (borderline); became P=6.93×10^-9 for rs11168048 in subset excluding asthma/COPD (per paper discussion).</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Significance strengthened when excluding asthma/COPD, suggesting context-specific effects.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Functional validation in humans lacking; link to cancer is indirect (airway inflammation/repair pathways).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.9">
                <h3 class="extraction-instance">Extracted Data Instance 9 (e141.9)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Behavioral smoking metrics</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Smoking status, smoking intensity, pack-years, and cessation-related behaviors</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Behavioral modifiers of pulmonary risk used and discussed in the study: current/past/never smoking, pack-years (dose × duration), and genetic influences on nicotine dependence and cessation that alter exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>covariates and stratified analyses within GWAS meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Variables assessed across CHARGE participants (N=20,890) with ever smokers N=11,963 and never smokers N=8,927. Pack-years calculated for current and past smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Greater pack-years and current smoking status associated with accelerated decline in pulmonary function and higher risk of COPD-related outcomes; genetic loci (e.g., CHRNA3/5) increase likelihood of heavier smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Never smoking and smoking cessation are protective; variants linked with successful cessation (FLJ20184 in other GWAS) may reduce long-term exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>CHARGE adjusted analyses for smoking status/pack-years; FLJ20184 cited from other work as containing variants associated with successful smoking cessation.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Age at initiation not specifically detailed in CHARGE methods but cumulative exposure (pack-years) and current vs past smoking were used; nicotine-dependence genes modify exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Behavioral metrics modulate exposure to tobacco smoke—the primary environmental carcinogen discussed.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Behavior determines dose of inhaled carcinogens; genetic predisposition to dependence magnifies exposure, increasing cumulative mutagenic/inflammatory insult.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Authors equate per-allele FEV1 effects (50–70 mL) to ~1.7–2.3 years of active-smoking-related decline (using 30 mL/year estimate), and to ~2.8–3.9 years of age-related decline (using ~18 mL/year). Pack-years included in regression models.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Some heavy smokers do not develop marked pulmonary decline/COPD, indicating other biological/genetic modifiers are operative.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Behavioral metrics are self-reported (smoking dose/duration), potential misclassification; age at initiation and other behavioral nuances not detailed.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.10">
                <h3 class="extraction-instance">Extracted Data Instance 10 (e141.10)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Environmental inhaled exposures</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Cigarette smoke, second-hand smoke, and other inhaled pollutants</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Environmental modifiers noted to accelerate pulmonary function decline and contribute to COPD risk; second-hand smoke quantitatively associated with small declines in FEV1 and discussed as benchmark comparisons to genetic effect sizes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>background/environmental modifiers referenced in meta-analysis</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Effects cited from external epidemiologic studies referenced in the paper (not re-measured in CHARGE for second-hand smoke estimates).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Active cigarette smoking is the dominant environmental risk; second-hand smoke exposure associated with modest FEV1 declines (10-year home exposure: –15 mL; 10-year workplace exposure: –41 mL). Other inhaled pollutants and occupational exposures are mentioned as contributors.</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Reduced exposure (avoiding smoking/second-hand smoke) is protective.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>Genes (e.g., GSTCD) that affect xenobiotic detoxification could modify the impact of these environmental exposures.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Time spent in environments with second-hand smoke and occupational exposures interact with personal smoking behavior to set total exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Active smoking, second-hand smoke, workplace exposures, and other inhaled pollutants; hyperoxia mentioned as an experimental modifier of Hh pathway in animal studies.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Inhaled toxins cause oxidative stress, DNA damage, inflammation, and remodeling; host detoxification and repair pathways mediate differential outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td>Second-hand smoke quantitative impacts from reference: 10-year home exposure = –15 mL FEV1; 10-year workplace exposure = –41 mL FEV1.</td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Magnitude of second-hand smoke effect is modest compared to heavy active smoking; individual susceptibility varies due to genetic modifiers.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>CHARGE did not directly measure second-hand smoke exposures comprehensively; cited numbers come from other studies.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e141.11">
                <h3 class="extraction-instance">Extracted Data Instance 11 (e141.11)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of factors that influence why only some cigarette smokers develop lung cancer, including genetic, environmental, behavioral, and biological mechanisms, as well as study results comparing smokers who develop lung cancer to those who do not.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Inflammation / tissue remodeling / detoxification mechanisms</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Biological mechanisms: inflammation, tissue remodeling, xenobiotic detoxification, epithelial repair and developmental signaling</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Recurring mechanistic themes linking genetic loci to pulmonary susceptibility include inflammatory signaling (AGER/RAGE), tissue remodeling (ADAM family), serotonergic modulation of airway reactivity (HTR4), xenobiotic detoxification (GSTCD), and developmental/repair signaling (Hh pathway, GPR126). These mechanisms can mediate differential vulnerability to smoking-related injury.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>mechanistic interpretations and literature-based discussion within GWAS paper</td>
                        </tr>
                        <tr>
                            <td><strong>population_description</strong></td>
                            <td>Mechanisms discussed in context of CHARGE genetic associations in adults of European ancestry (N=20,890).</td>
                        </tr>
                        <tr>
                            <td><strong>risk_factors_identified</strong></td>
                            <td>Variants that enhance pro-inflammatory signaling, impair detoxification, or dysregulate repair/morphogenesis are suggested to increase susceptibility to smoking-related lung damage (and by extension may affect risk of malignant transformation over time).</td>
                        </tr>
                        <tr>
                            <td><strong>protective_factors_identified</strong></td>
                            <td>Variants and pathways that support efficient detoxification (GST family), controlled inflammation, and effective epithelial repair could mitigate damage.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_findings</strong></td>
                            <td>AGER variant rs2070600 predicted to increase inflammatory signaling; GSTCD variants implicated in detoxification; ADAM family variants linked to remodeling; HHIP/PTCH1 implicate hedgehog signaling in repair and patterning.</td>
                        </tr>
                        <tr>
                            <td><strong>behavioral_modifiers</strong></td>
                            <td>Smoking increases the burden of toxins and injury that engage these mechanisms; genetic differences modulate the biological response to the same behavioral exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_modifiers</strong></td>
                            <td>Cigarette smoke and other inhaled pollutants provide the injurious stimuli that trigger these pathways.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Inflammation (AGER/RAGE), protease/anti-protease imbalance (alpha-1 AT background), remodeling via ADAMs, serotonergic airway reactivity (HTR4), xenobiotic detoxification (GSTCD), hedgehog-mediated developmental/repair responses (HHIP/PTCH1), and GPCR-mediated adhesion/signaling (GPR126).</td>
                        </tr>
                        <tr>
                            <td><strong>quantitative_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterexamples_or_exceptions</strong></td>
                            <td>Some loci show associations in never smokers or only in subsets, indicating mechanisms are not purely exposure-dependent and may reflect baseline developmental or structural traits.</td>
                        </tr>
                        <tr>
                            <td><strong>study_limitations</strong></td>
                            <td>Mechanistic assignments are inferential from gene function and prior literature; direct functional assays and longitudinal data linking these mechanisms to cancer incidence are not provided in this paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Genetics of chronic obstructive pulmonary disease <em>(Rating: 2)</em></li>
                <li>A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci <em>(Rating: 2)</em></li>
                <li>Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking <em>(Rating: 1)</em></li>
                <li>Clinical practice. Alpha1-antitrypsin deficiency <em>(Rating: 2)</em></li>
                <li>Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer <em>(Rating: 2)</em></li>
                <li>Increased levels of free serotonin in plasma of symptomatic asthmatic patients <em>(Rating: 1)</em></li>
                <li>Secondhand smoke exposure, pulmonary function, and cardiovascular mortality <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>